David A Zidar1, Steven Juchnowski, Brian Ferrari, Brian Clagett, Heather A Pilch-Cooper, Shawn Rose, Benigno Rodriguez, Grace A McComsey, Scott F Sieg, Nehal N Mehta, Michael M Lederman, Nicholas T Funderburg. 1. *Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH; †Department of Medicine, Case Western Reserve University/University Hospitals of Cleveland, Cleveland, OH; ‡National Heart, Lung and Blood Institute, Section of Inflammation and Cardiometabolic Diseases, Bethesda, MD; §National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD; ‖Rainbow Babies and Children's Hospital, Cleveland, OH; and ¶Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, Ohio State University, Columbus, OH.
Abstract
BACKGROUND: HIV infection is associated with increased cardiovascular risk, and this risk correlates with markers of monocyte activation. We have shown that HIV is associated with a prothrombotic monocyte phenotype, which can be partially mitigated by statin therapy. We therefore explored the relationship between oxidized low-density lipoprotein (oxLDL) particles and monocyte activation. METHODS: We performed phenotypic analysis of monocytes using flow cytometry on fresh whole blood in 54 patients with HIV and 24 controls without HIV. Plasma levels of oxLDL, soluble CD14, IL-6, and soluble CD163 were measured by enzyme-linked immunosorbent assay. In vitro experiments were performed using flow cytometry. RESULTS: Plasma levels of oxLDL were significantly increased in HIV infection compared with controls (60.1 units vs. 32.1 units, P < 0.001). Monocyte expression of the oxLDL receptors, CD36 and Toll-like receptor 4, was also increased in HIV. OxLDL levels correlated with markers of monocyte activation, including soluble CD14, tissue factor expression on inflammatory monocytes, and CD36. In vitro stimulation with oxLDL, but not to low-density lipoprotein, resulted in expansion of inflammatory monocytes and increased monocyte expression of tissue factor, recapitulating the monocyte profile we find in HIV disease. CONCLUSIONS: OxLDL may contribute to monocyte activation, and further study in the context of HIV disease is warranted.
BACKGROUND:HIV infection is associated with increased cardiovascular risk, and this risk correlates with markers of monocyte activation. We have shown that HIV is associated with a prothrombotic monocyte phenotype, which can be partially mitigated by statin therapy. We therefore explored the relationship between oxidized low-density lipoprotein (oxLDL) particles and monocyte activation. METHODS: We performed phenotypic analysis of monocytes using flow cytometry on fresh whole blood in 54 patients with HIV and 24 controls without HIV. Plasma levels of oxLDL, soluble CD14, IL-6, and soluble CD163 were measured by enzyme-linked immunosorbent assay. In vitro experiments were performed using flow cytometry. RESULTS: Plasma levels of oxLDL were significantly increased in HIV infection compared with controls (60.1 units vs. 32.1 units, P < 0.001). Monocyte expression of the oxLDL receptors, CD36 and Toll-like receptor 4, was also increased in HIV. OxLDL levels correlated with markers of monocyte activation, including soluble CD14, tissue factor expression on inflammatory monocytes, and CD36. In vitro stimulation with oxLDL, but not to low-density lipoprotein, resulted in expansion of inflammatory monocytes and increased monocyte expression of tissue factor, recapitulating the monocyte profile we find in HIV disease. CONCLUSIONS: OxLDL may contribute to monocyte activation, and further study in the context of HIV disease is warranted.
Authors: Shawn L Fultz; Kathleen A McGinnis; Melissa Skanderson; Margaret V Ragni; Amy C Justice Journal: Am J Med Date: 2004-03-15 Impact factor: 4.965
Authors: Valery N Bochkov; Diana Mechtcheriakova; Marcus Lucerna; Joakim Huber; Roland Malli; Wolfgang F Graier; Erhard Hofer; Bernd R Binder; Norbert Leitinger Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: S Ehara; M Ueda; T Naruko; K Haze; A Itoh; M Otsuka; R Komatsu; T Matsuo; H Itabe; T Takano; Y Tsukamoto; M Yoshiyama; K Takeuchi; J Yoshikawa; A E Becker Journal: Circulation Date: 2001-04-17 Impact factor: 29.690
Authors: Kyrill S Rogacev; Bodo Cremers; Adam M Zawada; Sarah Seiler; Nadine Binder; Philipp Ege; Gunnar Große-Dunker; Isabel Heisel; Florian Hornof; Jana Jeken; Niko M Rebling; Christof Ulrich; Bruno Scheller; Michael Böhm; Danilo Fliser; Gunnar H Heine Journal: J Am Coll Cardiol Date: 2012-09-19 Impact factor: 24.094
Authors: Cameron R Stewart; Lynda M Stuart; Kim Wilkinson; Janine M van Gils; Jiusheng Deng; Annett Halle; Katey J Rayner; Laurent Boyer; Ruiqin Zhong; William A Frazier; Adam Lacy-Hulbert; Joseph El Khoury; Douglas T Golenbock; Kathryn J Moore Journal: Nat Immunol Date: 2009-12-27 Impact factor: 25.606
Authors: Corrilynn O Hileman; Randi Turner; Nicholas T Funderburg; Richard D Semba; Grace A McComsey Journal: AIDS Date: 2016-01-02 Impact factor: 4.177